Research progress on pulmonary arterial denervation for pulmonary arterial hypertension
-
摘要: 交感神经过度激活加重肺动脉高压(pulmonary arterial hypertension，PAH)的进展，肺动脉去神经术(pulmonary artery denervation，PADN)是最近提出的一种有利于治疗PAH和混合型毛细血管后和前肺动脉高压(combined pre-capillary and post-capillary pulmonary hypertension，Cpc-PH)的介入方法，相关的临床试验初步证实了PADN的有效性及安全性。本文着重介绍PADN治疗的临床证据及操作流程。Abstract: Excessive activation of sympathetic nerves aggravates the progress of pulmonary arterial hypertension(PAH). Pulmonary artery denervation(PADN) is a new interventional approach for the treatment of PAH, as well as combined pre-capillary and post-capillary pulmonary hypertension(Cpc-PH). Preliminary trials have confirmed the efficacy and safety of PADN. This article focuses on the clinical evidence and procedure steps of PADN treatment.
-
-
[1] Humbert M, Kovacs G, Hoeper MM, et al, 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Respir J, 2023, 61(1): 2200879. doi: 10.1183/13993003.00879-2022
[2] Zelt J, Sugarman J, Weatherald J, et al. Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era[J]. Eur Respir J, 2022, 59(6).
[3] Velez-Roa S, Ciarka A, Najem B, et al. Increased sympathetic nerve activity in pulmonary artery hypertension[J]. Circulation, 2004, 110(10): 1308-1312. doi: 10.1161/01.CIR.0000140724.90898.D3
[4] Ciarka A, Doan V, Velez-Roa S, et al. Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension[J]. Am J Respir Crit Care Med, 2010, 181(11): 1269-1275. doi: 10.1164/rccm.200912-1856OC
[5] Kylhammar D, Kjellström B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension[J]. Eur Heart J, 2018, 39(47): 4175-4181. doi: 10.1093/eurheartj/ehx257
[6] Maron BA, Leopold JA. Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension: Part II: Neurohormonal Signaling Contributes to the Pulmonary Vascular and Right Ventricular Pathophenotype of Pulmonary Arterial Hypertension[J]. Circulation, 2015, 131(23): 2079-2091. doi: 10.1161/CIRCULATIONAHA.114.006980
[7] Zhang Y, Chen W, Xu Y, et al. Nerve distribution of canine pulmonary arteries and potential clinical implications[J]. Am J Transl Res, 2016, 8(2): 365-374.
[8] Zhou L, Zhang J, Jiang XM, et al. Pulmonary artery denervation attenuates pulmonary arterial remodeling in dogs with pulmonary arterial hypertension induced by dehydrogenized monocrotaline[J]. JACC Cardiovasc Interv, 2015, 8(15): 2013-2023. doi: 10.1016/j.jcin.2015.09.015
[9] Juratsch CE, Jengo JA, Castagna J, et al. Experimental pulmonary hypertension produced by surgical and chemical denervation of the pulmonary vasculature[J]. Chest, 1980, 77(4): 525-530. doi: 10.1378/chest.77.4.525
[10] Chen SL, Zhang YJ, Zhou L, et al. Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo[J]. EuroIntervention, 2013, 9(2): 269-276. doi: 10.4244/EIJV9I2A43
[11] Rothman AMK, Arnold ND, Chang W, et al. Pulmonary artery denervation reduces pulmonary artery pressure and induces histological changes in an acute porcine model of pulmonary hypertension[J]. Circ Cardiovasc Interv, 2015, 8(11): e002569. doi: 10.1161/CIRCINTERVENTIONS.115.002569
[12] Zhang H, Yu W, Zhang J, et al. Pulmonary artery denervation improves hemodynamics and cardiac function in pulmonary hypertension secondary to heart failure[J]. Pulm Circ, 2019, 9(2): 2045894018816297.
[13] Huang Y, Liu YW, Pan HZ, et al. Transthoracic pulmonary artery denervation for pulmonary arterial hypertension[J]. Arterioscler Thromb Vasc Biol, 2019, 39(4): 704-718. doi: 10.1161/ATVBAHA.118.311992
[14] Chen SL, Zhang FF, Xu J, et al. Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study(first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension)[J]. J Am Coll Cardiol, 2013, 62(12): 1092-1100. doi: 10.1016/j.jacc.2013.05.075
[15] Chen SL, Zhang H, Xie DJ, et al. Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: phase II results from the Pulmonary Artery Denervation-1 study[J]. Circ Cardiovasc Interv, 2015, 8(11): e002837. doi: 10.1161/CIRCINTERVENTIONS.115.002837
[16] Zhang H, Wei YY, Zhang CJ, et al. Pulmonary artery denervation for pulmonary arterial hypertension: A sham-controlled randomized PADN-CFDA trial[J]. JACC Cardiovasc Interv, 2022, 15(23): 2412-2423. doi: 10.1016/j.jcin.2022.09.013
[17] Hoeper MM, Bogaard HJ, Hoeper RC, et al. Definitions and diagnosis of pulmonary hypertension[J]. J Am Coll Cardiol, 2013, 62(25 Suppl): D42-D50.
[18] Tanai E, Frantz S. Pathophysiology of heart failure[J]. Compr Physiol, 2015, 6(1): 187-214.
[19] Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension[J]. J Am Coll Cardiol, 2013, 62(25 Suppl): D60-D72.
[20] Hwang IC, Kim YJ, Park JB, et al. Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials[J]. BMC Cardiovasc Disord, 2017, 17(1): 150. doi: 10.1186/s12872-017-0576-4
[21] Zhang H, Zhang J, Chen M, et al. Pulmonary artery denervation significantly increases 6-min walk distance for patients with combined pre-and post-capillary pulmonary hypertension associated with left heart failure: The PADN-5 Study[J]. JACC Cardiovasc Interv, 2019, 12(3): 274-284. doi: 10.1016/j.jcin.2018.09.021
[22] Romanov A, Cherniavskiy A, Novikova N, et al. Pulmonary artery denervation for patients with residual pulmonary hypertension after pulmonary endarterectomy[J]. J Am Coll Cardiol, 2020, 76(8): 916-926. doi: 10.1016/j.jacc.2020.06.064
-
下载:
图(2)
计量
- 文章访问数: 2459
- PDF下载数: 879
- 施引文献: 0